Verquvo Use In Pregnancy & Lactation

Pregnancy: There are no data from the use of vericiguat in pregnant women. Studies in animals have shown reproductive toxicity in presence of maternal toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). As a precautionary measure, vericiguat should not be used during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding: There is no information regarding the presence of vericiguat in human milk, the effects on the breastfed infant, or the effects on milk production. Vericiguat is present in the milk of lactating rats. A risk to the breastfed child cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue or abstain from vericiguat therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility: There are no data available on the effect of vericiguat on human fertility. In a study with male and female rats, vericiguat showed no impairment of fertility (see Pharmacology: Toxicology: Preclinical safety data under Actions).